LONDON, March 12, 2026, 19:35 GMT
- Smith & Nephew shares closed at 1,240.5 pence, down 0.24%, while the FTSE 100 finished 0.4% lower. 1
- The company on March 10 launched ALLEVYN COMPLETE CARE, a five-layer foam dressing for wound treatment and pressure-sore prevention, starting in the U.S. before a wider international rollout in 2026. 2
- Investors are still weighing a forecast $60 million tariff hit for 2026 and whether management can hold guidance through the year. 3
Smith & Nephew shares closed down 0.24% at 1,240.5 pence on Thursday, leaving the FTSE 100 medical-device maker in a choppy stretch days after it rolled out a new wound-care product. The wider London market was weaker too, with the blue-chip index down 0.4% as higher oil prices stirred inflation worries again. 1
That matters now because the March 10 launch of ALLEVYN COMPLETE CARE is one of the first visible pieces of Smith & Nephew’s 2026 product cycle, just after management wrapped up its three-year turnaround and reaffirmed guidance. Investors, though, remain fixed on the risks laid out with the annual results, including tariffs, conflict-linked supply disruption and the chance that guidance could come under pressure later this year. 2
Smith & Nephew said the five-layer foam dressing is designed for wound management and to help prevent pressure sores, with the U.S. first and launches across Europe and other markets due later in 2026. Rohit Kashyap, president of Advanced Wound Management, called it a “true next-generation dressing”, while biomedical engineer Amit Gefen said the design helps “dissipate shear forces” before they reach skin and tissue. 2
The commercial angle is real. Smith & Nephew says advanced wound management is a $12.5 billion market where it is the second-largest player by revenue; it names Convatec in dressings, while investors still benchmark its orthopaedics recovery against Stryker and Zimmer Biomet. That peer pressure is live: Convatec lifted its medium-term revenue growth target last month, helped by a stronger product pipeline and new wound-care products. 4
On March 2, Smith & Nephew reported 2025 revenue of $6.164 billion and company-defined trading profit of $1.211 billion, up 15.5%, and said 2026 trading profit should be about $1.3 billion on roughly 6% sales growth before currency effects. Chief executive Deepak Nath said a strong fourth quarter helped the group meet or beat its 2025 targets and pointed to a “strong cadence” of product launches in 2026. 5
Investors have not fully bought that case yet. The shares fell more than 5% on March 2, then rebounded 3.6% on March 3 after Barclays raised its price target; by Thursday’s close, the stock was still about 5% lower over five sessions. 3
The snag is that the launch does not clear the risk list. Smith & Nephew has warned of a $60 million tariff hit this year after a $17 million charge in 2025, and Nath told Reuters that a Suez Canal closure would lengthen shipping times from China to Europe. The company has also flagged softer wound-bioactives demand ahead of reimbursement changes, while RBC’s Jack Reynolds-Clark said there was “significant risk of guidance downgrades” over the year. 3
Nath has kept a steadier line, saying Smith & Nephew stood behind the 2026 guidance it gave on March 2. For now, the market looks like it wants proof that launches such as ALLEVYN can show up in margins and market share, not just in the product calendar. 3
